Home > Institute Collections > W500 > Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline glioma. > print

001     306282
005     20251119103719.0
024 7 _ |a 10.1016/j.xcrm.2024.101918
|2 doi
024 7 _ |a pmid:39809263
|2 pmid
024 7 _ |a pmc:PMC11866549
|2 pmc
037 _ _ |a DKFZ-2025-02508
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Erez, Nir
|b 0
245 _ _ |a Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline glioma.
260 _ _ |a Cambridge, MA
|c 2025
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763544989_2172553
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKFZ-MOST-Ca219#
520 _ _ |a The analysis of cell-free tumor DNA (ctDNA) and proteins in the blood of patients with cancer potentiates a new generation of non-invasive diagnostic approaches. However, confident detection of tumor-originating markers is challenging, especially in the context of brain tumors, where these analytes in plasma are extremely scarce. Here, we apply a sensitive single-molecule technology to profile multiple histone modifications on individual nucleosomes from the plasma of patients with diffuse midline glioma (DMG). The system reveals epigenetic patterns unique to DMG, significantly differentiating this group of patients from healthy subjects or individuals diagnosed with other cancer types. We further develop a method to directly quantify the tumor-originating oncoproteins, lysine 27 to methionine substitution in histone H3 (H3-K27M) and mutant p53, from <1 mL of plasma, allowing for the accurate molecular classification of patients with DMG. We show that our strategy correlates with MRI and droplet-digital PCR (ddPCR) measurements of ctDNA, highlighting the clinical potential of single-molecule-based, multi-parametric assays for DMG diagnosis and treatment monitoring.
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a DIPG
|2 Other
650 _ 7 |a H3-K27M
|2 Other
650 _ 7 |a TP53
|2 Other
650 _ 7 |a liquid-biopsy
|2 Other
650 _ 7 |a oncohistones
|2 Other
650 _ 7 |a single-molecule
|2 Other
650 _ 7 |a Nucleosomes
|2 NLM Chemicals
650 _ 7 |a Histones
|2 NLM Chemicals
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Circulating Tumor DNA
|2 NLM Chemicals
650 _ 7 |a Tumor Suppressor Protein p53
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Nucleosomes: metabolism
|2 MeSH
650 _ 2 |a Glioma: blood
|2 MeSH
650 _ 2 |a Glioma: genetics
|2 MeSH
650 _ 2 |a Glioma: diagnosis
|2 MeSH
650 _ 2 |a Glioma: pathology
|2 MeSH
650 _ 2 |a Histones: genetics
|2 MeSH
650 _ 2 |a Histones: blood
|2 MeSH
650 _ 2 |a Histones: metabolism
|2 MeSH
650 _ 2 |a Brain Neoplasms: blood
|2 MeSH
650 _ 2 |a Brain Neoplasms: genetics
|2 MeSH
650 _ 2 |a Brain Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Biomarkers, Tumor: blood
|2 MeSH
650 _ 2 |a Biomarkers, Tumor: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Circulating Tumor DNA: blood
|2 MeSH
650 _ 2 |a Tumor Suppressor Protein p53: blood
|2 MeSH
650 _ 2 |a Tumor Suppressor Protein p53: genetics
|2 MeSH
650 _ 2 |a Single Molecule Imaging: methods
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
700 1 _ |a Furth, Noa
|b 1
700 1 _ |a Fedyuk, Vadim
|b 2
700 1 _ |a Wadden, Jack
|b 3
700 1 _ |a Aittaleb, Rayan
|b 4
700 1 _ |a Adam, Tiffany
|b 5
700 1 _ |a Schwark, Kallen
|b 6
700 1 _ |a Niculcea, Michael
|b 7
700 1 _ |a Miclea, Madeline
|b 8
700 1 _ |a Mody, Rajen
|b 9
700 1 _ |a Franson, Andrea
|b 10
700 1 _ |a Parmar, Hemant A
|b 11
700 1 _ |a Ibrahim, Mohannad
|b 12
700 1 _ |a Lau, Benison
|b 13
700 1 _ |a Eze, Augustine
|b 14
700 1 _ |a Nourmohammadi, Niku
|b 15
700 1 _ |a Fried, Iris
|b 16
700 1 _ |a Nazarian, Javad
|b 17
700 1 _ |a Ron, Guy
|b 18
700 1 _ |a Venneti, Sriram
|b 19
700 1 _ |a Koschmann, Carl
|b 20
700 1 _ |a Shema, Efrat
|b 21
773 _ _ |a 10.1016/j.xcrm.2024.101918
|g Vol. 6, no. 1, p. 101918 -
|0 PERI:(DE-600)3019420-9
|n 1
|p 101918
|t Cell reports / Medicine
|v 6
|y 2025
|x 2666-3791
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP MED : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:51:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:51:29Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:51:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b CELL REP MED : 2022
|d 2024-12-05
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-05
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-05
980 _ _ |a journal
980 _ _ |a I:(DE-He78)W500-20160331
980 _ _ |a I:(DE-He78)W510-20160331
980 1 _ |a EXTERN4COORD

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21